Persistence of Antibody to Influenza A/H5N1 Vaccine Virus: Impact of AS03 Adjuvant

The adjuvant AS03 is stockpiled for future formulations with new and existing vaccines for the control of pandemic influenza virus. We previously reported the immunogenicity of an A/H5N1 vaccine extemporaneously mixed with the AS03 adjuvant for 42 days following vaccination. This report extends thos...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Vaccine Immunol
Main Authors: Chen, Wilbur H., Jackson, Lisa A., Edwards, Kathryn M., Keitel, Wendy A., Hill, Heather, Noah, Diana L., Creech, C. Buddy, Patel, Shital M., Mangal, Brian, Kotloff, Karen L.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2016
Assuntos:
Vaccines
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4711091/
https://ncbi.nlm.nih.gov/pubmed/26561390
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/CVI.00475-15
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados